For Research Purposes Only • Not For Human Consumption
Longevity / Specialty
ARA-290 10mg
Non-erythropoietic EPO-derived peptide — neuropathic and tissue-protection research.
$8011 LEFT
ARA-290 is an 11-amino-acid peptide derived from the helix B domain of erythropoietin. It activates the innate repair receptor without stimulating red blood cell production, and has been studied for small-fiber neuropathy, neuroinflammation and metabolic tissue protection.
Benefits
- Studied for reduction of neuropathic pain and small-fiber neuropathy symptoms
- Anti-inflammatory and tissue-protective signaling
- Supports corneal and epidermal nerve fiber density in trials
- No increase in hematocrit unlike EPO itself
Considerations
- Limited large-scale clinical data
- Effects typically require several weeks of consistent use
- Mild injection-site reactions reported
- Benefits may regress after discontinuation
Protocol
Subcutaneous injection once daily for 4–12 week research cycles, then reassess.
Dosage
Common research range: 1–4 mg per day.
Reconstitution
10 mg vial + 2 mL BAC water = 5 mg/mL (0.4 mL = 2 mg).
Always use bacteriostatic water (BAC), sterile technique and store reconstituted vials refrigerated unless otherwise noted.
Research Use Only. All information shown is summarized from publicly available research literature for educational reference only. These compounds are not approved for human consumption and nothing here is medical advice.
